GlassScriptPhysician profile
Robert H Mackie
NPI 1891797098
$691.81
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $80.94 · 2021: $13.64 · 2023: $72.33 · 2024: $92.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $157.25 | 2019-2020 | |
| Novo Nordisk INC | $99.96 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $61.53 | 2019-2024 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $52.08 | 2019 | |
| Abbvie INC. | $45.61 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $42.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.36 | 2019 | |
| Amgen INC. | $26.60 | 2021-2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $25.05 | 2019 | |
| Grifols USA, LLC | $23.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.55 | 2019-2020 | |
| Corium, LLC | $20.85 | 2024 | Azstarys |
| Horizon Therapeutics Plc | $17.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.80 | 2019 | |
| Astellas Pharma US INC | $15.43 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.10 | 2019 | |
| Lilly USA, LLC | $11.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mackie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.